<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085345</url>
  </required_header>
  <id_info>
    <org_study_id>ONCOTHER-MAC001</org_study_id>
    <secondary_id>CDR0000368637</secondary_id>
    <nct_id>NCT00085345</nct_id>
  </id_info>
  <brief_title>Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase II Study of Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, arsenic trioxide, and ascorbic&#xD;
      acid, work in different ways to stop cancer cells from dividing so they stop growing or die.&#xD;
      Arsenic trioxide and ascorbic acid may also help melphalan kill more cancer cells by making&#xD;
      them more sensitive to the drugs.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving melphalan together with arsenic&#xD;
      trioxide and ascorbic acid works in treating patients with relapsed or refractory multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the time to progression in patients with relapsed or refractory multiple&#xD;
           myeloma (MM) treated with melphalan, arsenic trioxide, and ascorbic acid.&#xD;
&#xD;
        -  Determine the response rate (combined complete response, partial response, and minimal&#xD;
           response) in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to response and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the effects of this regimen on renal failure associated with MM in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, multicenter study.&#xD;
&#xD;
      Patients receive oral melphalan once daily on days 1-4 of week 1 and arsenic trioxide (ATO)&#xD;
      IV over 1-2 hours and ascorbic acid IV over 15 minutes on days 1-4 of week 1 and then twice&#xD;
      weekly during weeks 2-5. Treatment repeats every 6 weeks for up to 6 courses in the absence&#xD;
      of disease progression or unacceptable toxicity. Patients with disease progression any time&#xD;
      after course 1 also receive oral prednisone once daily on days 1-4 and 22-25 of each course.&#xD;
      Patients achieving a complete response after 6 courses of therapy undergo bone marrow biopsy&#xD;
      and receive no further therapy. Patients achieving stable disease or a partial response after&#xD;
      6 courses of therapy continue to receive ATO and ascorbic acid once weekly.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <condition>Refractory Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascorbic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemosensitization/potentiation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma meeting at least 1 of the following criteria:&#xD;
&#xD;
          -  Relapsed disease after a response to standard first-line chemotherapy (e.g.,&#xD;
             vincristine, doxorubicin, and dexamethasone [VAD] OR melphalan and prednisone) or&#xD;
             first-line high-dose chemotherapy&#xD;
&#xD;
          -  Refractory disease (failed to achieve at least stable disease) to most recent&#xD;
             chemotherapy with or without systemic corticosteroids&#xD;
&#xD;
          -  Measurable disease, defined as a monoclonal immunoglobulin spike on serum&#xD;
             electrophoresis of ≥ 1 g/dL AND/OR urine monoclonal immunoglobulin spike of ≥ 200&#xD;
             mg/24 hours&#xD;
&#xD;
          -  No non-secretory myeloma&#xD;
&#xD;
          -  No plasma cell leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3 (30,000/mm^3 if bone marrow is extensively infiltrated)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Pancytopenia secondary to multiple myeloma or hypersplenism allowed&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2 times ULN (unless clearly related to disease)&#xD;
&#xD;
          -  No known active hepatitis B or C infection&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Calcium &lt; 14 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No evidence of acute ischemia or new conduction system abnormality by&#xD;
             electrocardiogram&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  No poorly controlled hypertension&#xD;
&#xD;
          -  No prolonged corrected QT interval (&gt; 460 ms) with potassium &gt; 4 mmol/L and magnesium&#xD;
             ≥ 1.8 mmol/L&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein, and skin changes)&#xD;
&#xD;
          -  No diabetes mellitus&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No known allergic reaction attributable to compounds of similar chemical or biological&#xD;
             composition to study drugs&#xD;
&#xD;
          -  No history of grand mal seizures&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy or antibody therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R. Berenson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oncotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Verde Hematology Oncology</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309-0633</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southbay Oncology / Hematology Medical Group</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Medical Group of Fresno, Incorporated</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Medical Group of Orange County, Incorporated</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates Medical Group - Redondo Beach</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Regional Oncology Center - Sotoyome</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Prevention and Treatment Center at Dominican and Watsonville Community Hospital</name>
      <address>
        <city>Soquel</city>
        <state>California</state>
        <zip>95073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Cancer Center - Vista</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncotherapeutics</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care - Roswell</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center at Tulane University Hospital and Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-2699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders at Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Royal Oak Campus</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists - Administrative Office</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

